Pulmatrix Reports Q1 Loss of 32 Cents Per Share
summarizeSummary
Pulmatrix reported a first-quarter loss of 32 cents per share. This financial update follows the company's recent 10-K filing in February, which detailed weak 2025 financials and an ongoing reverse merger with Cullgen Inc. expected to result in significant shareholder dilution. The continued quarterly loss underscores the persistent financial challenges for this micro-cap company, reinforcing the narrative of a difficult operating environment. Traders will be watching for further details on the Cullgen merger and subsequent financial reports for any signs of stabilization or continued pressure.
At the time of this announcement, PULM was trading at $1.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6M. The 52-week trading range was $1.16 to $9.37. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.